Quote:

---

I really don't understand why people here don't understand what Dr. Urano has plainly told us. I think there is a real scientific disconnect with shareholders here regarding MANF and wolframs/diabetes.

---

Here we go again with the small molecule post for the 1014th time. Back to the old Dave. I knew it couldn't last. I am sure Dr. Urano "prefers" people get well on their own with no treatments at all. The fact is Dr. Urano is looking/trying a lot of things. What's hard to understand about that.

You might want to try something more recent.

http://wolframsyndrome.dom.wustl.edu/orphan-d...signation/

Orphan Drug Designation - 23 Dec 2014

What is “Orphan Drug Designation”? If our drug receives an orphan drug designation from a regulatory agency, such as US FDA, it is easier to gain marketing approval, and there may be other financial incentives. This usually applies to a drug for a rare disease. I have just found out that Amarantus BioScience has received an orphan drug designation for MANF from FDA for treatment of retinitis pigmentosa. Because we are actively working on MANF for developing treatment for Wolfram syndrome, this is good news. If we get positive preclinical data, we have a chance to get an orphan drug designation for MANF for Wolfram syndrome . So I was quite encouraged by the news.


My last post to you Dave as you just repeat the same stuff over and over about small molecules. On ignore you go.